How did CSBR's revenue and expenses shift in Q3 2025?

Champions Oncology Inc (CSBR) experienced a significant shift in its revenue and expenses in Q3 2025, marked by notable improvements and strategic adjustments. Below is a detailed analysis:

1. Revenue Shift:
   • Record Revenue: CSBR reported a transformative quarter with record revenue of $17 million for Q3 2025
   • Revenue Growth: This represents a substantial increase, with a year-over-year growth of 41.8%. The growth was driven by the successful closure of an inaugural data deal and the expansion of data licensing business.
   • Revenue Structure: Data revenue contributed significantly, amounting to $4.5 million for the quarter, indicating early traction in the new licensing platform.
2. Expense Shift:
   • Cost Management: CSBR demonstrated effective cost management, as evidenced by a decrease in operating expenses. Total operating expenses decreased by 14.1% to $12.5 million compared to $14.6 million in the previous year.
   • Expense Reductions: Specific reductions were noted in general and administrative expenses, which dropped by 13.2% to $2.4 million. Research and development expenses also decreased significantly by 21.4% to $1.7 million compared to $2.2 million in the same quarter last year.
   • Profitability: The company's gross margin improved to 61%, supported by high-margin data revenue and operational efficiencies.
3. Financial Performance:
   • Net Income: CSBR reported a net income of $4.5 million for Q3 2025, a turnaround from a net loss of $2.5 million in the same quarter last year.
   • EBITDA: The company achieved a record high of $5.2 million in adjusted EBITDA, with income from operations reaching $4.5 million.
   • Stock Performance: Following the earnings release, the company's stock price closed at $9.79, representing a significant upswing of 54.660% in the last 3 months and 72.660% in the last 12 months.

In conclusion, CSBR's Q3 2025 financials reflect a company that has not only increased its revenue but also improved its operational efficiency and profitability. The strategic focus on data-driven growth and cost management has been pivotal in this turnaround.